Discovery could lead to new treatment for rare blood disease U of A cancer researcher proposes treating cutaneous T-cell lymphoma before it reaches the skin. January 27, By Adrianna Macpherson U of A dermatology researcher Robert Gniadecki discovered that cancer cells found in skin lesions on patients with T cell lymphoma originate from the blood, not the skin.
The discovery could lead to new ways of treating the rare form of blood cancer. Photo: Jordan Carson A cancer researcher at the University of Alberta has made a discovery that could unlock new ways to treat a rare blood disease.
By taking hodgkin cancer treatment of skin lesions from patients suffering from cutaneous T-cell lymphoma, U of A dermatology researcher Robert Gniadecki discovered that the cancer cells found in the lesions on the skin originate from the blood, not the skin as was believed. The protocol to treat the disease was to eliminate the cancer cells from the skin.
Based on his findings, Gniadecki believes it would be more effective to treat the malignant clones in the blood rather than waiting until the cells reach the skin and present as lesions. He also noted that even when a patient has a barely noticeable lesion, there is already an abundance of cancer cells in the blood.
Cutaneous T-cell lymphoma is a rare type of cancer that begins in T cells, which are part of the hodgkin cancer treatment system.
They develop mutations that cause them to attack skin cells causing lesions. Gniadecki is also working with the Alberta Machine Intelligence Institute Amii to run the genetic information from his samples through a machine learning program to see whether there are any identifiable biomarkers in the blood that could suggest how the disease progresses.
Complex cardiovascular disease after Hodgkin lymphoma treatment. Source: Romanian Journal of Cardiology. Hodgkin lymphoma survivors are at increased risk of therapy-related cardiac complications, risking premature morbidity and death. We report the case of a 43 years old woman that, after successful combined therapy for Hodgkin lymphoma, has developed, during the next fifteen years, multiple cardiac involvements: pericardial tamponade and constriction, valvular and myocardial dysfunction.
Because cutaneous T-cell lymphoma is so rare-roughly in the Edmonton area live with it-knowledge in the medical community about it is quite low and it's often not recognized early, said Gniadecki.
It's a huge medical need.